Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1837-1841

  Rack, Brigitte ^a   Schindlbeck, Christian ^a   Jückstock, Julia ^a   Genss, Eva Maria ^a   Hepp, Philip ^b   Lorenz, Ralf ^c   Tesch, Hans ^d   Schneeweiss, Andreas ^e   Beckmann, Matthias W ^f   Lichtenegger, Werner ^g   Sommer, Harald ^a   Friese, Klaus ^a   Janni, Wolfgang ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Praxis Lorenz/Hecker   (Germany)

^d Praxis Prof Tesch   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; CA 27.29; Chemotherapy; MUC 1; Tumor marker

Indexed keywords

CA 27-29 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; ZOLEDRONIC ACID;

ADULT; AGED; BREAST CANCER; CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; MUCIN-1; POSTMENOPAUSE; PREVALENCE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954604497     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, Fateh-Moghadam A and Seidel D: Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 86: 1217-1222, 2002.
2. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, Gatti C, Paccagnella A and Marubini E: Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38: 1181-1188, 2002.
3. Kumpulainen EJ, Keskikuru RJ and Johansson RT: Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76: 95-102, 2002.
4. Kokko R, Holli K and Hakama M: CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 38: 1189-1193, 2002.
5. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P and Miccoli P: Intensive postoperative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs. MCA and MCA-CA15.3 vs. CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 6: 269, 2006.
6. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007.
7. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I and Stieber P: Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 27: 1963-1968, 2007.
8. Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jager W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M and Domke I: Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 49: 15-24, 2003.
9. Singletary ES, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS and Greene FL: Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20: 3628-3636, 2002.
10. Le D, V, Tubiana HM, Friedman S, Hacene K, Spyratos F and Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914-1921, 1989.
11. Klee GG and Schreiber WE: MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med 128: 1131-1135, 2004.
12. Baldus SE, Wienand JR, Werner JP, Landsberg S, Drebber U, Hanisch FG and Dienes HP: Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol 27: 1289-1297, 2005.
13. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF and Ellis IO: Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18: 1295-1304, 2005.
14. Rahn JJ, Dabbagh L, Pasdar M and Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91: 1973-1982, 2001.
15. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR and Segal-Eiras A: Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 81: 195-207, 2003.
16. Bon GG, van Kamp GJ, Verstraeten RA, Mensdorff-Pouilly S, Hilgers J and Kenemans P: Quantification of MUC1 in breast cancer patients. A method comparison study. Eur J Obstet Gynecol Reprod Biol 83: 67-75, 1999.
17. Frenette PS, Thirlwell MP, Trudeau M, Thomson DM, Joseph L and Shuster JS: The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumour Biol 15: 247-254, 1994.
18. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K and Robertson JF: CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37: 355-363, 2001.
19. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ and Evelegh M: Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15: 2322-2328, 1997.
20. Eskelinen M, Tikanoja S and Collan Y: Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor. Anticancer Res 9: 437-439, 1989.
21. Fehm T, Gebauer G and Jager W: Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 75: 97-106, 2002.
22. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14: 2843-2877, 1996.
23. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH and Lee KS: Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19: 675-681, 2008.
24. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J and O'Higgins N: High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 50: 559-563, 2004.
25. Lynch DM, Rogers PE, Love JC, Salkas MJ, Skarphol KA, Gross ME, Lu MG, Petrides VH, Bruzek DJ, Cox JL, Jones KA, Kelley CA and Chan DW: Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA. Tumour Biol 19: 421-438, 1998.
26. Canizares F, Sola J, Perez M, Tovar I, De Las HM, Salinas J, Penafiel R and Martinez P: Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 22: 273-281, 2001.
27. Shering SG, Sherry F, McDermott EW, O'Higgins NJ, and Duffy MJ: Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 83: 2521-2527, 1998.
28. Cannon PM, Ellis IO, Blarney RW, Bell J, Elston CW and Robertson JF: Expression of tumour-associated antigens in breast cancer primary tissue compared with serum levels. Eur J Surg Oncol 19: 523-527, 1993.